Theravance Biopharma
TBPH
121 hedge funds and large institutions have $431M invested in Theravance Biopharma in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 47 reducing their positions, and 15 closing their positions.
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
3% more funds holding
Funds holding: 118 → 121 (+3)
1.05% more ownership
Funds ownership: 98.55% → 99.61% (+1.1%)
4% less call options, than puts
Call options by funds: $22K | Put options by funds: $23K
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
22% less capital invested
Capital invested by funds: $552M → $431M (-$121M)
26% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$9.27M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$2.38M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$1.55M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.52M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$7.65M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.44M |
| 3 |
BlackRock
New York
|
-$3.52M |
| 4 |
Jane Street
New York
|
-$3.13M |
| 5 |
NM
Newtyn Management
New York
|
-$2.37M |
TBPH Hedge Fund Activity: Q1 2024 in Review
121 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2024, worth a combined $431M — down 22% from $552M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TBPH positions and 15 closed out — a net gain of 4 holders — while 35 added to existing stakes and 47 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $9.27M. The largest seller was Baupost Group, cutting an estimated $7.65M.
- 121 institutional investors held Theravance Biopharma (TBPH) as of Q1 2024, up from 118 in Q4 2023.
- Funds reported $431M of Theravance Biopharma stock for Q1 2024, down 22% quarter-over-quarter.
- 19 funds opened new Theravance Biopharma positions in Q1 2024 and 15 closed out, a net change of +4 holders.
- The largest Theravance Biopharma buyer in Q1 2024 was Camber Capital Management, an estimated $9.27M added.
- The largest Theravance Biopharma seller in Q1 2024 was Baupost Group, an estimated $7.65M sold.
Based on aggregated 13F filings for Q1 2024.